Sapna Patel, MD

Professional Titles

• Dr. William Robinson Endowed Chair in Cancer Research
• Professor

Publications

• Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE 3rd, Wada DA, Plaza JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Chmielowski B, Khushalani NI, Markowitz J, Monroe M, Contreras CM, Bowles T, Norman K, Medina E, Gonzalez CR, Baselga-Carretero I, Garcilazo IP, Vega-Crespo A, Chen JM, Deen NNA, Patel SP, Grossmann KF, Sondak VK, Sharon E, Moon J, Wu MC, Ribas A. Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial. Nat Cancer. 2026 Feb;7(2):272-282. PubMed PMID: 41611998
• Gouda MA, Zarifa A, Yang Y, Stephen B, Gurses SA, Sprenger A, Tian Y, Derbala MH, Oliva IG, Meric-Bernstam F, Patel SP. Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial. J Immunother Precis Oncol. 2025 Feb;8(1):82-88. PubMed PMID: 39816915
• Borgers JSW, Medina TM, Robinson WA, Couts KL, Katsnelson EN, Muckle CM, Davilla E, Patel SP, Gao D, Tobin RP, McCarter MD. Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update. Ther Adv Med Oncol. 2025;17:17588359251349321. PubMed PMID: 40574966
• Burton EM, Milton DR, Tetzlaff MT, Wani K, Ross MI, Postow MA, Lazcano R, Glitza IC, Wong MK, Patel SP, Diab A, Gershenwald JE, McQuade JL, Betof Warner A, Prieto VG, Lee JE, Goepfert RP, Fisher SB, Song A, Malke J, Simon JM, Ariyan C, Torres-Cabala CA, Davies MA, Lazar A, Wargo JA, Tawbi HA, Amaria RN. Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma. J Clin Oncol. 2025 Sep 10;43(26):2856-2862. PubMed PMID: 40638872
• Hasanov M, Kiany S, Forget MA, Bassett R, Davies MA, Diab A, Gershenwald JE, Glitza IC, Lee JE, Lucci A, McQuade JL, Patel SP, Ross MI, Tawbi HA, Wargo JA, Wong MK, Bernatchez C, Hwu P, Haymaker C, Amaria RN. Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma. Oncoimmunology. 2025 Dec;14(1):2546402. PubMed PMID: 40815607
• Javaid A, Patel SP, Larkin J. Tumour-infiltrating lymphocytes in refractory melanoma-not as hard as we thought?. Ann Oncol. 2025 Oct;36(10):1116-1118. PubMed PMID: 40701439
• Patel SP, Sheth RA, Davis C, Medina T. Combination Immunotherapy With Nivolumab Plus Ipilimumab in Melanoma of Unknown Primary. J Clin Oncol. 2025 Mar 10;43(8):907-911. PubMed PMID: 39913893
• Schmitt AM, Larkin J, Patel SP. Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still Out. J Clin Oncol. 2025 Jan 10;43(2):122-124. PubMed PMID: 39374477
• Pike SB, Reid MW, Peng CC, Chang C, Xu BY, Gombos DS, Patel S, Xu L, Berry JL. Multicentre analysis of nucleic acid quantification using aqueous humour liquid biopsy in uveal melanoma: implications for clinical testing. Can J Ophthalmol. 2025 Feb;60(1):e23-e31. PubMed PMID: 38036045
• Burton EM, Milton DR, Tetzlaff MT, Wani K, Ross MI, Postow MA, Lazcano R, Glitza IC, Wong MK, Patel SP, Diab A, Gershenwald JE, McQuade JL, Betof Warner A, Prieto VG, Lee JE, Goepfert RP, Fisher SB, Song A, Malke J, Simon JM, Ariyan C, Torres-Cabala CA, Davies MA, Lazar A, Wargo JA, Tawbi HA, Amaria RN. Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma. J Clin Oncol. 2025 Sep 10;43(26):2856-2862. PubMed PMID: 40638872
• Othus M, Sharon E, Wu MC, Sondak VK, Ribas A, Patel SP. Design considerations for randomized comparisons of neoadjuvant-adjuvant versus adjuvant-only cancer immunotherapy when tumor measurement schedules do not align (SWOG S1801). Clin Trials. 2025 Oct;22(5):571-577. PubMed PMID: 40099861
• MacBeth ML, Bagby SM, Borgers JSW, Turner JA, Anderson KC, Whitty PA, Hartman S, Yacob B, Rebecca VW, Davila E, Pitts TM, Medina TM, Patel SP, McCarter MD, Robinson WA, Tobin RP, Couts KL. Decitabine reverses innate immune gene suppression in rare melanomas. bioRxiv. 2025 Aug 28. PubMed PMID: 40909489
• Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE 3rd, Wada DA, Plaza JA, Sosman JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Khushalani NI, Markowitz J, Negrea G, Kasbari S, Doolittle GC, Swami U, Roberts T, Mathew BN, Medina E, Baselga-Carretero I, Gonzalez CR, Garcilazo IP, Vega-Crespo A, Chen JM, Naser Al-Deen N, Patel SP, Sharon E, Moon J, Wu MC, Ribas A. Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial. Nat Med. 2025 Aug 14. [Epub ahead of print] PubMed PMID: 40813711
• Borgers JSW, Medina TM, Robinson WA, Couts KL, Katsnelson EN, Muckle CM, Davilla E, Patel SP, Gao D, Tobin RP, McCarter MD. Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update. Ther Adv Med Oncol. 2025;17:17588359251349321. PubMed PMID: 40574966
• Najjar YG, Orloff M, Mitchell TC, Bowles TL, Betof Warner A, Bollin K, Chandra S, Cohen JV, Eroglu Z, Funchain P, Gaughan E, Glitza Oliva I, Hsu S, Hu-Lieskovan S, Kennedy LB, Truong TG, McKean M, Mehnert J, Moon H, Tsai KK, Wilson M, Tran T, Buchbinder EI, Fecher LA, Guild S, Patel SP. Proceedings of the seventh annual Women in Melanoma Conference. Ther Adv Med Oncol. 2025;17:17588359251342039. PubMed PMID: 40535733
• Gouda MA, Zarifa A, Yang Y, Stephen B, Gurses SA, Sprenger A, Tian Y, Derbala MH, Oliva IG, Meric-Bernstam F, Patel SP. Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial. J Immunother Precis Oncol. 2025 Feb;8(1):82-88. PubMed PMID: 39816915
• Chattopadhyay C, Roszik J, Bhattacharya R, Alauddin M, Mahmud I, Yadugiri S, Ali MM, Khan FS, Prabhu VV, Lorenzi PL, Wei B, Burton E, Morey RR, Lazcano R, Davies MA, Patel SP, Grimm EA. Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma. Br J Cancer. 2024 Dec;131(11):1846-1857. PubMed PMID: 39394450
• Gouda MA, Stephen B, Tian Y, Alshawa A, Onwugaje DOC, Albittar A, Yang Y, Zarifa A, Yilmaz B, Gurses S, Sprenger A, Derbala MH, Brink A, How JA, Moyers J, Piha-Paul SA, Hong DS, Meric-Bernstam F, Patel SP, Oliva IG. A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma. J Immunother Precis Oncol. 2024 Nov;7(4):247-254. PubMed PMID: 39524469
• Turcios Escobar S, Yang R, Nelson KC, Gershenwald JE, Tawbi H, Aung PP, Patel SP, Torres-Cabala CA. Utility of next-generation sequencing in the diagnosis of metastatic melanoma: A case report. J Cutan Pathol. 2024 Sep;51(9):644-648. PubMed PMID: 38757469
• Saberian C, Milton DR, Simon J, Amaria RN, Diab A, McQuade J, Patel SP, Tawbi H, Yee C, Wong MK, McCutcheon IE, Davies MA, Ferguson SD, Glitza Oliva IC. Survival and treatment outcomes in patients with leptomeningeal disease from metastatic melanoma. Neurooncol Pract. 2024 Aug;11(4):452-463. PubMed PMID: 39006528
• Sheth RA, Wehrenberg-Klee E, Patel SP, Brock KK, Fotiadis N, de Baère T. Intratumoral Injection of Immunotherapeutics: State of the Art and Future Directions. Radiology. 2024 Jul;312(1):e232654. PubMed PMID: 39078294
• Seervai RNH, Taylor MM, Rahbar Z, Patel SP, Nelson KC, Prieto VG, Curry JL. Keratosis Pilaris-Like Reaction Associated With Chromatin Remodeling Complex Inhibition in Uveal Melanoma. JAMA Dermatol. 2024 Jun 1;160(6):682-685. PubMed PMID: 38717752
• Chattopadhyay C, Roszik J, Bhattacharya R, Alauddin M, Mahmud I, Yadugiri S, Ali MM, Khan FS, Prabhu VV, Lorenzi P, Burton E, Morey RR, Lazcano R, Davies MA, Patel SP, Grimm EA. Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma. bioRxiv. 2024 Jan 15. PubMed PMID: 38293232
• VanderWalde A, Bellasea SL, Kendra KL, Khushalani NI, Campbell KM, Scumpia PO, Kuklinski LF, Collichio F, Sosman JA, Ikeguchi A, Victor AI, Truong TG, Chmielowski B, Portnoy DC, Chen Y, Margolin K, Bane C, Dasanu CA, Johnson DB, Eroglu Z, Chandra S, Medina E, Gonzalez CR, Baselga-Carretero I, Vega-Crespo A, Garcilazo IP, Sharon E, Hu-Lieskovan S, Patel SP, Grossmann KF, Moon J, Wu MC, Ribas A. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med. 2023 Sep;29(9):2278-2285. PubMed PMID: 37592104
• Patel SP, Othus M, Chen Y, Wright GP Jr, Yost KJ, Hyngstrom JR, Hu-Lieskovan S, Lao CD, Fecher LA, Truong TG, Eisenstein JL, Chandra S, Sosman JA, Kendra KL, Wu RC, Devoe CE, Deutsch GB, Hegde A, Khalil M, Mangla A, Reese AM, Ross MI, Poklepovic AS, Phan GQ, Onitilo AA, Yasar DG, Powers BC, Doolittle GC, In GK, Kokot N, Gibney GT, Atkins MB, Shaheen M, Warneke JA, Ikeguchi A, Najera JE, Chmielowski B, Crompton JG, Floyd JD, Hsueh E, Margolin KA, Chow WA, Grossmann KF, Dietrich E, Prieto VG, Lowe MC, Buchbinder EI, Kirkwood JM, Korde L, Moon J, Sharon E, Sondak VK, Ribas A. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023 Mar 2;388(9):813-823. PubMed PMID: 36856617

Practice Locations

• University of Colorado Hospital

• University of Colorado Cancer Center

Specialty Information

• Medical Oncology